Changeflow GovPing Pharma & Drug Safety Electroporation Apparatus and Methods Patent Ap...
Routine Notice Added Draft

Electroporation Apparatus and Methods Patent Application

Email

Summary

The USPTO has published a patent application (US20260085268A1) filed by MaxCyte, Inc. on September 6, 2023. The application describes an apparatus and methods for electroporation of cells, including safety features like an emergency stop button. This is a new patent application and does not impose new regulatory requirements.

What changed

The United States Patent and Trademark Office (USPTO) has published a new patent application, US20260085268A1, filed by MaxCyte, Inc. The application details an apparatus and methods for electroporation of cells, focusing on a system that includes a high voltage module, a low voltage module with a user interface, and a single board computer. A key feature highlighted is an electronic circuit designed to receive, latch, and process signals from an emergency stop button to safely terminate voltage application and disable processor commands to the high voltage module.

This publication represents a new patent application and does not constitute a final rule or guidance with immediate compliance obligations. However, companies involved in cell therapy, drug development, or medical device manufacturing, particularly those utilizing electroporation technology, should be aware of this filing. The assignee, MaxCyte, Inc., is a known entity in this space, and the patent's claims, if granted, could impact future product development and intellectual property landscapes in the biotechnology and medical device sectors.

Source document (simplified)

← USPTO Patent Applications

APPARATUS AND METHODS FOR ELECTROPORATION

Application US20260085268A1 Kind: A1 Mar 26, 2026

Assignee

MaxCyte, Inc.

Inventors

Sergey Mikhailovych DZEKUNOV, Nicholas CHOPAS, Stephen PORTER

Abstract

An apparatus and methods for electroporation of cells are disclosed. The apparatus comprises a memory storing instructions, a high voltage module to apply a voltage to cells, a low voltage module including a user interface, a system board connected to the high voltage module, the low voltage module, and a single board computer, and the single board computer including at least one processor to control the high voltage module and the low voltage module. The system board includes an emergency stop button and an electronic circuit. The electronic circuit receives a signal from the emergency stop button, latches the signal from the emergency stop button, blocks a logical signal controlling the voltage delivered to the instrument output, terminates the voltage applied to cells, and disables the at least one processor to provide commands to the high voltage module.

CPC Classifications

C12M 35/02 C12M 41/48 C12N 13/00

Filing Date

2023-09-06

Application No.

19109342

View original document →

Named provisions

Abstract Assignee Inventors

Classification

Agency
USPTO
Instrument
Notice
Legal weight
Non-binding
Stage
Draft
Change scope
Minor
Document ID
US20260085268A1

Who this affects

Applies to
Drug manufacturers Medical device makers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3345 Medical Device Manufacturing 3254.1 Biotechnology
Activity scope
Cell Therapy Drug Development
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Research & Development
Topics
Medical Devices Biotechnology

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: Patent Apps - Biotech (C12N) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.